According to Sciencedaily's editors, a group of neuroscientists at Georgetown University Medical Center have developed and even successfully tested a drug that reduces the accumulation of toxic proteins and other decay products. Thus, it is possible to prevent and treat neurodegenerative diseases such as Parkinson's and Alzheimer's and to rehabilitate after motor dysfunction by stroke.
On October 22, experts at an international conference of the Society of Neurobiologists in Chicago presented test results for a substance code-named CM101. The compound CM101 stimulates the removal of damaged folded proteins and toxic products from the brain. These include alpha synclines, tau and beta amyloids, which are responsible for the development of a number of neurodegenerative processes in the central nervous system.
A very low dose of CM101 accelerates the elimination of proteins from brain neurons by several hours. This is just enough to ensure the removal of neurotoxic proteins from cells and the intercellular space, "says Charbel Mussa, Ph.D.
This work is a continuation of a study by scientists on how drugs known as tyrosine kinase inhibitors can enhance protein removal and possibly stop neurodegenerative diseases. Previous work has led experts to clinical trials of two cancer drugs that are tyrosine kinase inhibitors (TCS) – nilotinib and bosutinib. These two drugs are prescribed to patients for doses of leukemia that are ten times higher than what is needed to eliminate the accumulation of protein in neurons.
While investigating drugs and their effects on metabolic processes, the researchers noted that the two drugs mentioned above inhibit a variety of brain tyrosine kinases, thereby improving the elimination of toxic products. A number of molecules that scientists synthesized and received CM101 play a leading role in this process.
We are redeveloping cancer medicines to help people get rid of neurodegenerative disorders. Our studies show that this strategy works well in neurons that are affected but have not died under the influence of toxins.
According to scientists, CM101 has passed extensive tests in several series of laboratory animal tests that have caused artificially neurodegenerative diseases. In most cases, it was possible to achieve maximum protein excretion and improve brain function. The animals also improved coordination and memory. By the way, we are constantly reporting the success of this kind of research. We therefore recommend that you subscribe to our channel in telegram in order to always be up to date.
See also: Scientists have found a region of the brain from which Alzheimer's disease originated
The next step in the work is to investigate the toxicity of the drug and to identify its side effects. The possibility of the drug's effect on other organs and tissues, particularly on the bone marrow and hematopoietic system, can not be ruled out because the drug has "anti-oncological roots". Once the safety of the CM101 has been proven, a large-scale trial of the new drug in humans will begin.